Mesoblast Revenue Rises 44% as Operating Cash Spend Falls 86%
MSB: $2.32 +23.40% · MC: $2.6B
Mesoblast reported first-quarter Ryoncil net revenue of US$28 million, up 44% from a year earlier, while operating cash spend fell 86% to approximately US$2 million. The company held US$99 million in cash at quarter-end. It completed treatment of all patients in its pivotal chronic low back pain trial, with the primary result expected next year, and began enrolling adults in a Ryoncil registration trial. The FDA also confirmed that a planned application for rexlemestrocel-L may proceed for certain heart failure patients with life-threatening gastrointestinal bleeding.

Comments